Ozempic maker's CEO blames insurance companies for weight-loss drug prices
The chief executive of the company behind Ozempic and Wegovy blamed insurers and middlemen for the high costs of weight-loss drugs in the U.S. during a congressional testimony on Tuesday.
Blame drug 'middlemen' for the high price of Ozempic and Wegovy, Novo Nordisk CEO tells Congress
CEO Lars Fruergaard Jørgensen will shift the blame for the high prices of the company’s popular weight loss treatments to drug middlemen and the ‘complex’ U.S. health care system today during a committee hearing in Congress.
'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing
Novo Nordisk 's NVO CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medication and often hailed as a “miracle” weight loss drug, Ozempic will soon be eligible for U.S. government price negotiations, potentially within the next year.
Novo Nordisk CEO prepares to defend Ozempic, Wegovy US pricing at Senate hearing
After circling Novo Nordisk and its high GLP-1 drug prices for months, Sen. | Ahead of a hearing on Ozempic and Wegovy prices, prepared remarks from Novo CEO Lars Fruergaard Jørgensen shine a light on the larger U.
Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices
Key Takeaways Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing of weight-loss drugs Wegovy and Ozempic.The committee accused the company of charging "outrageously high prices" for the treatments.
Novo Nordisk CEO faces US Congress scrutiny over weight-loss drug pricing
U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,
Novo Nordisk CEO set to defend Ozempic, Wegovy prices on Capitol Hill
The CEO of Novo Nordisk is set to face pointed questions on Capitol Hill Tuesday about the prices of the Danish pharmaceutical giant’s blockbuster drugs Ozempic and Wegovy.
Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices
Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo Nordisk’s Ozempic and Wegovy if the company lowers the prices of the treatments. It’s Sanders’ latest move to pressure Novo to cut the prices of the blockbuster diabetes and obesity therapies.
Novo says Ozempic to be eligible for US price negotiations in less than a year
Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard Jorgensen said in his written testimony on Monday.
Novo CEO Blames Ozempic’s High Cost on Drug Middlemen’s Tactics
Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...
Novo CEO to blame drug middlemen
The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...
Live news: Trafigura appoints Richard Holtum as chief executive
Trafigura has appointed Richard Holtum as chief executive, replacing Jeremy Weir who will become chair of the Swiss trading ...
devdiscourse2h
Health Roundup: US Donates 1M Mpox Vaccines, AstraZeneca Disappoints in Breast Cancer Trial, Novo Faces Scrutiny
This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...
Benzinga.com15d
Lars Fruergaard Jorgensen's Net Worth
Who is Lars Fruergaard Jorgensen? Lars Fruergaard Jorgensen does not have any significant net worth to report based on the numbers we have. This is based on reported shares in ZYMOGENETICS ...